RFL RFL

Rafael Stock Price

FREE RFL REPORT

18.10
0.00 (0.0%)
18.10
Volume 0
Bid Price
Ask Price
News -
Company Name Stock Ticker Symbol Market Type
Rafael Holdings Inc RFL AMEX Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 18.10 19:00:00
Open Price Low Price High Price Close Price Prev Close
18.10
Trades Volume Avg Volume
0 0 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 18.10 USD

Period:

Draw Mode:

Rafael Holdings Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 442.96M 24.47M 18.77M $ 410.00k $ - -6.46 -4.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -84.08k 6.50%

more financials information »

Rafael News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical RFL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years3.0530.863.0513.4453,74415.05493.44%

Rafael Description

Rafael Holdings includes commercial real estate assets and interests in two clinical-stage pharmaceutical companies backed by a strong and liquid balance sheet. Rafael's real estate holdings are comprised by a 20-story commercial office building and associated parking garage in Newark, New Jersey, an office/data center building in Piscataway, New Jersey and an office condominium in Israel. Rafael's pharmaceutical holdings include interests in two clinical-stage oncology companies - Rafael Pharmaceuticals and LipoMedix. Rafael Pharmaceuticals is developing therapies that exploit the metabolic differences between normal cells and cancer cells in both solid and liquid cancers. LipoMedix is developing liposomal prodrugs designed to enhance the efficacy of certain chemotherapeutic therapies.